De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Avalon GloboCare Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Avalon GloboCare te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Real Estate winstgroei	36.5%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Oct 06

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

Jan 30

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

Jan 04

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Nov 30

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Avalon GloboCare onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

NasdaqCM:ALBT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	-8	-15	-4	-4	N/A
3/31/2024	-7	-15	-6	-6	N/A
12/31/2023	-7	-17	-7	-7	N/A
9/30/2023	2	-10	-8	-8	N/A
6/30/2023	1	-13	-9	-9	N/A
3/31/2023	1	-13	-8	-8	N/A
12/31/2022	1	-12	-7	-7	N/A
9/30/2022	1	-12	-7	-7	N/A
6/30/2022	1	-8	-5	-5	N/A
3/31/2022	1	-9	-4	-4	N/A
12/31/2021	1	-9	-5	-5	N/A
9/30/2021	1	-10	-5	-5	N/A
6/30/2021	1	-11	-6	-6	N/A
3/31/2021	1	-12	-7	-7	N/A
12/31/2020	1	-13	-8	-8	N/A
9/30/2020	1	-15	-8	-8	N/A
6/30/2020	1	-16	-7	-7	N/A
3/31/2020	2	-17	-8	-8	N/A
12/31/2019	1	-18	-7	-7	N/A
9/30/2019	1	-15	-6	-6	N/A
6/30/2019	1	-14	-6	-6	N/A
3/31/2019	1	-11	-5	-5	N/A
12/31/2018	2	-8	-4	-4	N/A
9/30/2018	2	-7	-5	-4	N/A
6/30/2018	1	-5	-4	-3	N/A
3/31/2018	1	-4	N/A	-1	N/A
12/31/2017	1	-3	N/A	-1	N/A
9/30/2017	1	-2	N/A	-1	N/A
6/30/2017	1	-1	N/A	-1	N/A
3/31/2017	1	0	N/A	0	N/A
12/31/2016	1	0	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van ALBT boven de spaarquote ( 2.5% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van ALBT naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van ALBT naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van ALBT naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van ALBT naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ALBT naar verwachting over 3 jaar hoog zal zijn

Avalon GloboCare Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Avalon GloboCare Corp., Annual General Meeting, Oct 08, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

Avalon GloboCare Corp. Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

The Nasdaq Stock Market, LLC Grants Avalon GloboCare a 180-Day Extension to October 28, 2024 to Regain Compliance with the Minimum Bid Price Requirement

Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Corp. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$0.14 loss per share (vs US$0.56 loss in 3Q 2022)

Avalon Globocare Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market as Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Avalon GloboCare Corp., Annual General Meeting, Oct 12, 2023

Second quarter 2023 earnings released: US$0.25 loss per share (vs US$0.23 loss in 2Q 2022)

Avalon GloboCare Corp. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.28 loss per share (vs US$1.07 loss in FY 2021)

Avalon GloboCare Corp. announced that it expects to receive $11 million in funding

Avalon GloboCare Regains Compliance with the Minimum Bid Requirement

Avalon Globocare Appoints Lourdes Felix, to Its Board of Directors

Avalon GloboCare Corp., Annual General Meeting, Dec 29, 2022

Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.024 loss in 3Q 2021)

Insufficient new directors

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into an agreement to acquire 60% stake in Laboratory Services MSO, LLC for $31 million.

We Think Avalon GloboCare (NASDAQ:AVCO) Has A Fair Chunk Of Debt

Avalon GloboCare Receives Second Letter from the Staff of Nasdaq

Second quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 2Q 2021)

Avalon GloboCare Corp. Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer

Avalon GloboCare Corp. announced that it has received $3.718943 million in funding

Insufficient new directors

Would Avalon GloboCare (NASDAQ:AVCO) Be Better Off With Less Debt?

Avalon GloboCare Corp. Appoints Hongxing Liu to Scientific and Clinical Advisory Board

First quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings released: US$0.11 loss per share (vs US$0.16 loss in FY 2020)

Does Avalon GloboCare (NASDAQ:AVCO) Have A Healthy Balance Sheet?

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

Third quarter 2021 earnings released: US$0.024 loss per share (vs US$0.04 loss in 3Q 2020)

Here's Why Avalon GloboCare (NASDAQ:AVCO) Can Afford Some Debt

Director William Stilley has joined 3rd company board

Second quarter 2021 earnings released: US$0.028 loss per share (vs US$0.039 loss in 2Q 2020)

Avalon GloboCare Corp.(NasdaqCM:AVCO) dropped from Russell Microcap Value Index

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into a definitive agreement to acquire Hebei Senlang Biotechnology Inc., Ltd. for approximately CNY 640 million.

Avalon Globocare to acquire SenlangBio in all-stock deal

First quarter 2021 earnings released: US$0.028 loss per share (vs US$0.043 loss in 1Q 2020)

Is Avalon GloboCare (NASDAQ:AVCO) A Risky Investment?

Full year 2020 earnings released: US$0.16 loss per share (vs US$0.24 loss in FY 2019)

A Look At Avalon GloboCare's (NASDAQ:AVCO) Share Price Returns

New 90-day high: US$1.59

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

New 90-day high: US$1.33

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Third quarter 2020 earnings released: US$0.04 loss per share

New 90-day low: US$1.12

Avalon GloboCare Provides Clinical Updates on its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical Trial

New 90-day low: US$1.15

New 90-day low - US$1.54

First half earnings released

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven